$CLVS ~ Rubraca ARIEL-3 (ovarian maintenance therapy) hits all endpoints. http://phx.corporate-ir.net/phoenix.zhtml?c=247187&p=irol-newsArticle_Print&ID=2281511 one analyst has $126 PT ..imo, CLVS will be bought out by big pharma soon.